Navigation Links
Medical Diagnostic Laboratories, L.L.C. Announces a Complimentary Reflex Test to Determine Azithromycin Resistance in Chlamydia Trachomatis
Date:9/11/2012

HAMILTON, N.J., Sept. 11, 2012 /PRNewswire/ -- Medical Diagnostic Laboratories, L.L.C. (MDL), a CLIA-certified infectious disease laboratory which specializes in high complexity, state-of-the-art, automated DNA-based molecular analyses, announced that it is now offering an azithromycin resistance reflex assay for Chlamydia trachomatis. MDL is believed to be the first and only clinical laboratory to offer the antibiotic resistance for this sexually transmitted pathogen. Drug resistance testing has become an essential tool to assist clinicians in the selection of appropriate drug regimens for effective treatment. The azithromycin resistance reflex assay for Chlamydia trachomatis will be performed at no additional charge when Chlamydia trachomatis is detected in a patient's specimen.

Chlamydia is the most frequently reported sexually transmitted disease in the United States and is caused by the bacterium Chlamydia trachomatis. In 2010, over 1.3 million chlamydial infections were reported to the Centers for Disease Control and Prevention (CDC) from 50 states and the District of Columbia. Asymptomatic infection is very common in both men and women and can therefore "silently" cause irreversible damage before symptoms are experienced or a proper diagnosis is made. Left untreated, a chlamydial infection can spread to a woman's uterus and fallopian tubes, and cause pelvic inflammatory disease (PID), ectopic pregnancy, and infertility.

To prevent the spread of the chlamydial infection and cure the patient, an effective treatment must be initiated as quickly as possible. Although most genital infections caused by Chlamydia trachomatis are effectively treated with azithromycin, recent studies indicate that a subset of strains are resistant to this antibiotic. This detection of resistance of Chlamydia trachomatis to azithromycin is therefore important when choosing proper antibiotic therapy. MDL has developed a molecular diagnostic sequencing assay that can detect these specific azithromycin-resistant Chlamydia trachomatis strains. This test is now being performed at no additional charge for any positive Chlamydia trachomatis specimens that have been detected by MDL's real-time PCR diagnostic assay.

Dr. Eli Mordechai, Chief Executive Officer (CEO), in announcing the new assay, stated: "We are pleased to add reflexive testing for azithromycin resistance to our Chlamydia trachomatis assay. The molecular-based testing that we have developed can discriminate between antibiotic susceptible and resistant infections. This information allows a physician, at the time of diagnosis, to provide the most rapid and cost-effective treatment to their patients. Recognizing the importance of the increasing antibiotic resistance among human pathogens, MDL is the only laboratory to now offer molecular diagnostic antibiotic resistance testing at no additional charge for three of the most common sexually transmitted diseases: Neisseria gonorrhoeae, Trichomonas vaginalis, and now for the first time, Chlamydia trachomatis."

MDL is a member of the Genesis Biotechnology Group located in Hamilton, New Jersey in "Einstein's Alley," the research and technology corridor of New Jersey, in close proximity to major metropolitan centers in New York, New Jersey and Pennsylvania.

To find out more about this test and other MDL testing, please visit www.mdlab.com.

Contact: Martin Adelson, Ph.D.
madelson@mdlab.com
609.570.1015
www.mdlab.com

This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Medical Diagnostic Laboratories, L.L.C.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Medical Marijuana, Inc. Portfolio Company PhytoSPHERE Systems Announces Successful Production of Hemp Harvesting for High Value CBD Oil
2. AFCell Medical Reports Results from the Retrospective Study of a Novel Allograft Membrane to Prevent Post-Operative Adhesions in the Repair of Peroneal and Posterior Tibial Tendons
3. Tufts Medical Center Announces Inaugural INNOVATION Day: Innovating a Path to Market
4. Texas Medical Center, the largest concentration of medical research, educational and healthcare organizations in the world, announces the first Houston Stem Cell Summit to highlight the latest stem cell research and commercialization efforts
5. Global Medical Laboratories Industry
6. MarketsandMarkets: Global Refurbished Medical Equipments Market worth $8.45 Billion by 2017
7. Medical Marijuana Inc. Product, CanChew Bio-Technologies
8. The Leukemia & Lymphoma Society Awards $12 Million in Research Grants in Four Critical Areas of Unmet Medical Need
9. Elsevier / MEDai Names Dr. Peter Edelstein as Chief Medical Officer and Dr. Gerald Osband as Director of Product Strategy
10. Former FDA Inspectors Train Medical Device, Pharmaceutical Companies How to Prepare for FDA Inspections of Their Quality Systems
11. Department of Defense Exercises Options Under Contract for Nerve Agent Medical Countermeasure Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... , ... March 22, 2017 , ... ... human tissue regeneration from small lab samples to full-size tissues, bones, even whole ... establish a vascular system that delivers blood deep into the developing tissue. ...
(Date:3/22/2017)... , March 22, 2017  UBM and the ... announce their extended partnership and the third annual Massachusetts ... by the 21 st Annual MassMEDIC Conference ... place May 3-4, 2017. MassMEDIC ... Association (ADVAMED) President and CEO, Scott Whitaker ...
(Date:3/22/2017)... 22, 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... www.oramed.com ), a clinical-stage pharmaceutical company ... systems, announced today that Dr. Miriam Kidron ... presentation titled, "Oral Insulin for Diabetes Treatment: Bypassing ... Institute,s Oligonucleotide and Peptide Therapeutics (OPT) Boston Conference in ...
(Date:3/22/2017)... York , March 22, 2017 ... largely fragmented, states a research report by Transparency Market ... Pfizer Inc., Amgen Inc., and AbbVie Inc., accounted for ... 2015. The prominent players in this market are focusing ... their product portfolio, which is likely to lead to ...
Breaking Biology Technology:
(Date:2/14/2017)... N.C. , Feb. 14, 2017  Wake Forest ... M.D., as its new chief executive officer (CEO). Freischlag ... CEO John D. McConnell , M.D., who last ... position at the Medical Center, after leading it since ... the full scope of Wake Forest Baptist,s academic health ...
(Date:2/10/2017)... Research and Markets has announced the addition ... and Commercial Aspects" to their offering. ... Biomarkers play an ... for selection of treatment as well for monitoring the results. ... in modern medicine. Biochip/microarray technologies and next generation sequencing are ...
(Date:2/8/2017)... 7, 2017  Aware, Inc. (NASDAQ: AWRE ), ... financial results for its quarter and year ended December 31, ... 2016 was $3.9 million compared to $6.9 million in the ... of 2016 was $0.6 million compared to $2.6 million in ... quarter of 2016 was $0.5 million, or $0.02 per diluted ...
Breaking Biology News(10 mins):